Last reviewed · How we verify
adjuvant chemotherapy with 5-FU associated with oxaliplatin — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
adjuvant chemotherapy with 5-FU associated with oxaliplatin (adjuvant chemotherapy with 5-FU associated with oxaliplatin) — University of Sao Paulo General Hospital.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| adjuvant chemotherapy with 5-FU associated with oxaliplatin TARGET | adjuvant chemotherapy with 5-FU associated with oxaliplatin | University of Sao Paulo General Hospital | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- adjuvant chemotherapy with 5-FU associated with oxaliplatin CI watch — RSS
- adjuvant chemotherapy with 5-FU associated with oxaliplatin CI watch — Atom
- adjuvant chemotherapy with 5-FU associated with oxaliplatin CI watch — JSON
- adjuvant chemotherapy with 5-FU associated with oxaliplatin alone — RSS
Cite this brief
Drug Landscape (2026). adjuvant chemotherapy with 5-FU associated with oxaliplatin — Competitive Intelligence Brief. https://druglandscape.com/ci/adjuvant-chemotherapy-with-5-fu-associated-with-oxaliplatin. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab